Syndax Pharmaceuticals, Inc.
SNDXDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How SNDX's past catalysts played out
Revumenib
Colorectal Cancer
Intensive Chemotherapy Regimen
Acute Myeloid Leukemias
Aromatase Inhibitor (AI) Therapy
ER+ Breast Cancer
cobicistat
Acute Myeloid Leukemia
Axatilimab
Chronic Graft-versus-host-disease
avelumab
Epithelial Ovarian Cancer
entinostat
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Revumenib | Phase 3 | Colorectal Cancer | - | - |
Intensive Chemotherapy Regimen | Phase 3 | Acute Myeloid Leukemias | - | - |
Aromatase Inhibitor (AI) Therapy | Phase 2 | ER+ Breast Cancer | - | - |
cobicistat | Phase 2 | Acute Myeloid Leukemia | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
avelumab | Phase 2 | Epithelial Ovarian Cancer | - | - |
entinostat | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Syndax Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Syndax Pharmaceuticals, Inc.'s (SNDX) pipeline across Phase 3, Phase 2. Its lead program is Revumenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Syndax Pharmaceuticals, Inc.'s next FDA catalyst?→
Syndax Pharmaceuticals, Inc.'s (SNDX) next tracked catalyst is a Earnings expected November 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNDX biotech catalysts?→
Add SNDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Syndax Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.